The Morrison Government is providing unprecedented funding to help our best and brightest health and medical researchers translate their ideas into new treatments and breakthrough cures for patients.
The four-year, $22.3 million Biomedical Translation Bridge (BTB) funding program will be open for applications from Australian health and medical research innovators from 17 February 2020.
SMEs and research organisations will be able to access up to $1 million in funding to accelerate development of their biological, pharmaceutical, medical and health technology projects along the translation and commercialisation pathway.
This is the second round of funding from the BTB program, with the first round supporting eight projects following a competitive application process.
The BTB program is funded from the Government’s landmark $20 billion Medical Research Future Fund, which aims to transform health and medical research and innovation to improve lives, build the economy and contribute to health system sustainability.
The Morrison Government is backing the development of new life-saving medicines, devices and treatments.
Taking a project from an idea to a final product is a long and expensive process – and this is why the BTB program is so important.
Through BTB, we are able to fund and nurture early-stage health and medical research – which is the first step towards groundbreaking treatments – to reach proof-of-concept with the potential to attract further capital and support.
It helps researchers transform today’s ideas into new treatments to help tomorrow’s patients, and I urge Australian innovators to start preparing their funding applications now.
The BTB program is operated by MTPConnect, a not-for-profit organisation formed to accelerate the growth of Australia’s medical technology, biotechnology and pharmaceutical sector.
Applications for funding through the BTB program open on 17 February and close on 6 March 2020.